Eisai/Biogen’s Leqembi Will See Broadened Access To Majority Of Patients
Full Approval For Alzheimer’s Triggers CMS Coverage
CMS will cover Leqembi now that the US FDA has converted Leqembi’s accelerated approval to traditional approval, giving most patients eligible for treatment access to the drug. Updated labeling puts greater emphasis on safety concerns.
